Lu Hongbo
SEC Form 4 insider trading activity
Lu Hongbo has filed 6 SEC Form 4 filings (7 transaction rows) across 2 companies, including ARWR, ZBIO, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: May 14, 2026.
On the most recent filing, Lu Hongbo is listed as Director at ARROWHEAD PHARMACEUTICALS, INC. Inside the rolling window, Lu Hongbo reported 2 open-market purchases totaling $2.2M in ZBIO and 1 open-market sale totaling $228K in ARWR. The largest disclosed transaction in the window is a purchase of 78,768 ZBIO shares on Mar 31, 2026, worth $1.6M.
Companies traded
Other insiders at ARWR
Insider Buying
$2.2M
reported purchases (SEC code P)
Insider Selling
$228K
reported sales (SEC code S)
Companies
2
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
Frequently asked questions
How many SEC Form 4 filings has Lu Hongbo made?
Lu Hongbo has filed 6 SEC Form 4 filings (7 transaction rows) across 2 companies, including ARWR, ZBIO since 2025.
Which companies does Lu Hongbo trade?
Lu Hongbo has filed SEC Form 4 disclosures for 2 companies, including ARWR, ZBIO.
When was Lu Hongbo's most recent SEC Form 4 filing?
Lu Hongbo's most recent SEC Form 4 filing on Tracefour is dated May 14, 2026.
What is Lu Hongbo's total buy and sell value in the current window?
Inside the rolling retention window, Lu Hongbo bought $2.2M and sold $228K based on SEC Form 4 filings.
What was Lu Hongbo's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 78,768 ZBIO shares on 2026-03-31, worth $1.6M, per SEC Form 4 filings.